Clinical trial
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent…
NCT00103194 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00103194 |
|---|---|
| Title | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer |
| Official title | Phase II Trial of GW572016 in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | lapatinib ditosylate, laboratory biomarker analysis |
| Enrollment | 49 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Feb 8, 2005 |
| Last update posted | Sep 30, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: